David Spriggs

USPTO Granted Patents = 8 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 17(Granted Patents)

Company Filing History:

7 out of 559

Memorial Sloan Kettering Cancer Center

patents

1 out of 48

Eureka Therapeutics, Inc.

patents

1 out of 512

Sloan-kettering Institute for Cancer Research

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180285 - Antibodies to galectin-3 and methods of use thereof (2024-12-31),

2. 12168696 - Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer (2024-12-17),

3. 11834513 - Antibodies to MUC16 and methods of use thereof (2023-12-05),

4. 11066480 - Anti-MUC16 antibodies and uses thereof (2021-07-20),

5. 10759869 - Antibodies to MUC16 and methods of use thereof (2020-09-01),

6. 9790283 - Antibodies to MUC16 and methods of use thereof (2017-10-17),

7. 9493580 - Multivalent glycopeptide constructs and uses thereof (2016-11-15),

8. 9169328 - Antibodies to MUC16 and methods of use thereof (2015-10-27),

Title: The Innovative Contributions of David Spriggs

Introduction

David Spriggs is a prominent inventor based in New York, NY, known for his significant contributions to the field of cancer research. With a total of eight patents to his name, he has made remarkable strides in developing innovative therapies aimed at treating various forms of cancer. His work focuses on the creation of antibodies that target specific proteins associated with cancer progression.

Latest Patents

Among his latest patents, one notable invention is related to antibodies that specifically bind to galectin-3 (LGALS3). This patent outlines compositions, methods, and uses for these antibodies, which are crucial in managing, treating, or preventing disorders such as cancer. Another significant patent involves antibodies to mucin-16 (MUC16), which includes encoding polynucleotides and methods for treating MUC16-positive cancer. This invention also provides methods for managing and preventing diseases associated with positive MUC16 expression.

Career Highlights

David Spriggs has had a distinguished career, working with esteemed organizations such as Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, David has collaborated with notable colleagues, including Dharmarao Thapi and Javier Morales. These partnerships have fostered an environment of innovation and have

This text is generated by artificial intelligence and may not be accurate.